Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD Raises Stock Position in Cellebrite DI Ltd. (NASDAQ:CLBT)

Key Points

• Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD increased its stake in Cellebrite DI Ltd. by 9.2% during the first quarter, now holding 380,081 shares worth approximately $7.38 million.
• Cellebrite DI's most recent quarterly earnings showed an EPS of $0.10, exceeding estimates, with a revenue of $107.55 million, despite a negative net margin of 46.34%.
• The stock currently holds a consensus rating of "Buy" from analysts with an average target price of $22.43, indicating confidence in the stock's potential for growth.

Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD raised its stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 9.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 380,081 shares of the company's stock after purchasing an additional 31,908 shares during the period. Cellebrite DI accounts for about 1.8% of Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD's portfolio, making the stock its 17th biggest position. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD owned about 0.16% of Cellebrite DI worth $7,381,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently modified their holdings of the stock. Assetmark Inc. purchased a new position in shares of Cellebrite DI during the first quarter valued at approximately $33,000. Catalyst Capital Advisors LLC bought a new stake in shares of Cellebrite DI during the 1st quarter worth approximately $51,000. Gen Wealth Partners Inc purchased a new position in Cellebrite DI during the 4th quarter valued at $85,000. NewEdge Advisors LLC grew its position in Cellebrite DI by 600.7% in the 4th quarter. NewEdge Advisors LLC now owns 3,910 shares of the company's stock valued at $86,000 after acquiring an additional 3,352 shares during the last quarter. Finally, Sigma Planning Corp purchased a new stake in Cellebrite DI in the first quarter worth $233,000. Institutional investors own 45.88% of the company's stock.

Cellebrite DI Price Performance

CLBT stock opened at $14.32 on Friday. Cellebrite DI Ltd. has a 1-year low of $11.90 and a 1-year high of $26.30. The business has a 50-day moving average price of $15.80 and a 200 day moving average price of $18.72. The company has a market capitalization of $3.43 billion, a P/E ratio of -14.92, a PEG ratio of 2.94 and a beta of 1.28.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of $0.09 by $0.01. Cellebrite DI had a negative net margin of 46.34% and a positive return on equity of 35.36%. The business had revenue of $107.55 million during the quarter, compared to analyst estimates of $109.36 million. During the same quarter in the previous year, the business posted $0.08 EPS. The company's quarterly revenue was up 20.0% compared to the same quarter last year. On average, analysts anticipate that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Needham & Company LLC reissued a "buy" rating and set a $24.00 target price on shares of Cellebrite DI in a research note on Friday, June 6th. JPMorgan Chase & Co. lowered their price objective on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating for the company in a research report on Monday, May 12th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Cellebrite DI has a consensus rating of "Buy" and an average target price of $22.43.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.

Want to see what other hedge funds are holding CLBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.